NYSE$EVH
Evolent Health Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Evolent Health's Q2 2021 performance reflected revenue increase, strategic acquisitions, and raised full-year guidance.
Evolent Health announced its Q2 2021 financial results with a revenue of $222.1 million, a net loss of $(9.1) million, and an adjusted EBITDA of $13.3 million. The company has raised its full-year 2021 guidance. They also entered into an agreement to acquire Vital Decisions and added new provider partnerships.
- GAAP revenue reached $222.1 million, a 2.2% increase year-over-year.
- Net loss attributable to common shareholders was $(9.1) million.
- Adjusted EBITDA increased to $13.3 million from $10.5 million in the prior year.
- Total lives managed reached 12.2 million.
Headline financials
Revenue & EPS history
Evolent Health · Revenue · Quarterly
$222M
Revenue by segment
Evolent Health · $92.7M total across 3 segments · Q3 2023
- Cases$37.4M—40.3%
- Performance Suite$32.8M—35.4%
- Administrative Services$22.5M—24.3%
Forward guidance
Evolent Health expects revenue to be in the range of $870 million to $900 million and Adjusted EBITDA to be in the range of $50 million to $58 million for the year ending December 31, 2021. For the third quarter 2021, revenue is expected to be in the range of $215 million to $230 million and Adjusted EBITDA is expected to be in the range of $11 million to $15 million.
Tailwinds
- Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $870 million to $900 million.
- Previous revenue guidance was $845 million to $880 million.
- Adjusted EBITDA is expected to be in the range of approximately $50 million to $58 million.
- Previous Adjusted EBITDA guidance was $42 million to $52 million.
- For the three months ending September 30, 2021, revenue is expected to be in the range of approximately $215 million to $230 million.
Headwinds
- Adjusted EBITDA is expected to be in the range of approximately $11 million to $15 million for the three months ending September 30, 2021.
- Actual results may differ materially.
- Factors that may cause actual results to differ materially from our current expectations are set forth in Evolent Health, Inc.'s filings with the Securities and Exchange Commission.
- Uncertainty in the health care regulatory framework, including the potential impact of policy changes
- Risks related to completed and future acquisitions, investments, alliances and joint ventures
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
-1.9%
Avg return
30 days after
65%
32 / 49 earnings
Positive
+29.2%
Q2 2024
Best reaction
-46.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.5% | +8.6% | +9.9% | |
| Q4 2025 | +25.0% | +39.8% | -13.7% | |
| Q3 2025 | -17.5% | -25.8% | -34.3% | |
| Q1 2025 | -16.2% | -17.1% | -22.7% | |
| Q4 2024 | -2.6% | -11.8% | -10.6% | |
| Q3 2024 | -46.1% | -41.7% | -55.0% | |
| Q2 2024 | +29.2% | +28.5% | +49.3% | |
| Q1 2024 | -10.3% | -12.5% | -13.9% | |
| Q4 2023 | +13.8% | +14.1% | +8.3% | |
| Q3 2023 | +13.5% | +18.4% | +20.4% | |
| Q2 2023 | -7.5% | -4.6% | -14.2% | |
| Q1 2023 | -4.3% | -0.9% | -11.4% | |
| Q4 2022 | +9.1% | +9.0% | -4.4% | |
| Q3 2022 | -10.8% | -22.4% | -1.2% | |
| Q2 2022 | +4.9% | +2.7% | +6.2% | |
| Q1 2022 | +0.9% | -8.5% | +4.0% | |
| Q4 2021 | +13.9% | +16.4% | +34.8% | |
| Q3 2021 | +3.4% | +0.3% | -10.4% | |
| Q2 2021 | +3.5% | +2.9% | +13.5% | |
| Q1 2021 | +8.2% | +11.7% | +5.2% | |
| Q4 2020 | -3.1% | -6.9% | -0.9% | |
| Q3 2020 | +6.9% | +15.3% | +41.0% | |
| Q2 2020 | +8.3% | +8.8% | +13.7% | |
| Q1 2020 | +12.6% | +11.4% | -1.6% | |
| Q4 2019 | -13.7% | -18.2% | -48.0% | |
| Q3 2019 | +16.3% | +29.7% | -14.4% | |
| Q2 2019 | +9.3% | +17.2% | +13.4% | |
| Q1 2019 | -1.3% | +0.9% | -34.6% | |
| Q4 2018 | -3.5% | -8.8% | -14.2% | |
| Q3 2018 | +14.5% | +10.8% | -8.5% | |
| Q2 2018 | +1.4% | +5.0% | +17.2% | |
| Q1 2018 | +8.4% | +12.8% | +36.4% | |
| Q4 2017 | +1.0% | +5.5% | -1.7% | |
| Q3 2017 | -13.4% | -27.5% | -16.0% | |
| Q2 2017 | -17.6% | -23.7% | -25.9% | |
| Q1 2017 | +3.3% | +5.0% | +14.2% | |
| Q4 2016 | +5.7% | +1.2% | +8.0% | |
| Q3 2016 | -3.1% | -9.7% | -13.9% | |
| Q2 2016 | +3.8% | +9.6% | +3.1% | |
| Q1 2015 | +0.7% | — | — | |
| Q1 2016 | +14.5% | — | — | |
| Q4 2013 | +3.9% | — | — | |
| Q1 2014 | +3.9% | — | — | |
| Q2 2015 | +3.9% | — | — | |
| Q4 2015 | +14.6% | — | — | |
| Q3 2014 | +12.0% | — | — | |
| Q3 2015 | +11.8% | — | — | |
| Q2 2014 | -8.5% | — | — | |
| Q4 2014 | -8.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro